Abstract: Scaffold-based tissue engineering approaches have been under investigation for more than 30 years now and many different techniques have been developed in order to engineer various tissues of the body.
Introduction
The term "Tissue Engineering" (TE) was originally defined in a wide-ranging and general perspective in 1988 by Skalak and Fox as "the application of the principles and methods of engineering and life sciences towards the fundamental understanding of structure-function relationships in normal and pathological mammalian tissues and the development of biological substitutes to restore, maintain, or improve functions" [1] . Widespread recognition of the set phrase TE followed in 1993 with perhaps the single most cited and influential review paper in the field by Langer and Vacanti [2] . In their paper the authors defined three general strategies for creating new tissue, namely the use of (1) isolated cells and substitutes, (2) tissueinducing substances (signaling molecules such as growth factors) and (3) cells placed on scaffolds and/or matrices. Today, the definition of these three general strategies has been commonly adopted by the TE field in a large plethora of studies targeting to regenerate any type of tissue and organ in the human body. The first purely cell-based strategy is defined as cell transplantation where cells in a small volume of media or cell sheets are injected or transplanted into the body. The second strategy focuses on the use of different types of bioactive substances to elicit specific reactions in the host body. Here, biochemical substances (such as growth factors, surface peptides, etc.) are used to mediate biochemical signals to the inhomogeneous cell population of the host tissue to encourage migration, proliferation, and finally differentiation in the defect site to repair/regenerate the tissue. The third (and most commonly applied) strategy is isolating specific cell types and culturing them in a three-dimensional environment mimicking the natural extracellular matrix before implantation. These specific three-dimensional environments can for example be created with sandwich cultures, hydrogels, and/or cells in specifically configured matrices (hydrogels) or cellular solids (also defined as scaffolds). Due to the multitude of options in developing strategies and technology platforms, tissue engineering is a highly complex research area requiring substantial interdisciplinary research efforts. Even though there is a clear definition of tissue engineering which most people in the field accept, there is often a lack of clear distinction between the terms "scaffold" and "matrix", and they are often used synonymously. In this review the authors will use the definition by Williams [3] , that a scaffold is defined as a cellular solid and a matrix is defined as a hydrogel. This review focuses on the design and fabrication of scaffold for tissue engineering. However, the authors would like to recommend excellent reviews recently published by Malda et al. [4] and Melchels et al. [5] for further reading on hydrogels for biofabrication.
Over the last three decades, the field of tissue engineering and regenerative medicine has received considerable scientific and economical interest. With the general increase in live expectancy and the development of increasingly specific diagnostic tools to identify organ pathophysiologies at early stages, the clinical (and social) demand for repair and replacement of damaged and/or malfunctioning organs is growing. When tissue engineering was introduced in the 1990s expectations were high that we would be able to replace damaged organs with new organs from the lab bench soon. The possibilities envisioned created a hype in popular media and "tissue engineer" was named number one of the ten hottest job of the future by Time Magazine in 2000 [6] .
The field of Tissue engineering (TE) and its clinical application Regenerative Medicine (RM) have seen remarkable scientific progress over the last 30 years, but we are still far away from "pulling a newly engineered organ out of the Petri dish". Successful applications of newly developed tissue engineering products have mainly resulted from identification of products that can be translated from bench to bedside with available technology and under existing regulatory guidelines [7] . However, there is a striking contrast between (private and governmental) TE research expenditures over the last decades and the resulting numbers of commercially available products [8] . There is also a significant discrepancy between the complexity of TE therapies undergoing scientific evaluation compared to the actual therapeutic concepts that have reached clinical application so far [9] .
Current challenges in TE research are to identify emerging rules for organ regeneration and to translate these into scaffold design parameter as simply yet effective as possible in order to achieve substantial clinical translatability [10] . To achieve widespread routine clinical application, TE constructs must be reduced to basic crucial properties ( = as easy to handle as possible), involve minimal post-processing after fabrication and must be able to be manufactured in a reproducible, controlled process at economical costs and speed. Simplifying our TE approaches as much as possible and using the body's endogenous healing capacity for an in situ TE are current challenges in this field of research [11] [12] [13] [14] . For TE scaffolds in particular, we need to develop biomimetic scaffold designs that enable and promote stepwise remodelling of the surrounding tissues including the newly formed extracellular matrix (ECM). The challenge will be to create scaffolds that resemble the natural ECM generating downstream bioactive molecules during their degradation processes while providing sufficient mechanical stability at the same time [15] .
In this review the authors discuss the unmet clinical needs that inspire these designs, the physiological factors that pose difficult challenges for their realization, and viable technologies that promise robust solutions for bone regeneration. We are looking to define general requirements for TE scaffold properties and to highlight major constraints, with an emphasis on bone tissue engineering. We then also review current state-of-the-art scaffold manufacturing techniques in the light of the before identified requirements and constraints on scaffold design and provide a future outlook.
Scaffold design
Scaffold-based tissue engineering approaches have been investigated for various tissues including skin, respiratory system (lung, trachea), intestine, liver, kidney, heart, blood vessels, nervous system, endocrine organs (e.g., thyroid, pancreas), and musculoskeletal tissues [16, 17] . Although each specific tissue has its very own unique requirements regarding scaffold design and structure, there are general scaffold design requirements that apply to all scaffold-based strategies used in TE.
In general, scaffolds should be made from highly biocompatible materials that do not elicit an adverse permanent immune response in the host tissue after implantation. However, it has to be kept in mind that eliciting a (controlled) immune response to the implanted biomaterial can be beneficial for tissue engineering as well. For example, calcium phosphate particles used in bone TE are known to cause initial inflammatory reactions after being implanted, subsequently stimulating osteoprogenitor cell differentiation and bone matrix deposition [18] . Porosity is another prerequisite for scaffolds used in tissue engineering as it allows for adequate cell-matrix interactions and cell migration/seeding. However, the exact pore size and porosity required to create ideal local conditions differs from tissue to tissue. An average pore diameter of 20-125 µm is required to achieve regeneration for skin tissue, with smaller pores excluding cells from the scaffold interior and larger pore sizes hampering the accommodation of cells in direct contact with the scaffold surface (favouring cell-cell cluster and/or sheets instead) [10] . For bone tissue however, larger pore sizes ( > 300 µm) and higher porosity lead to increased neovascularisation promoting higher rates of new bone formation by direct osteogenesis, while small pores favour hypoxic conditions leading to osteochondral formation before osteogenesis takes place [19] . Besides biocompatibility and porosity/pore size, surface properties of the scaffold have to be designed to promote attachment, migration, proliferation and differentiation of cell types of interest. The biological properties of a scaffold depend fundamentally on the complex interplay between and scaffold surface and biological fluids of the host, that is amongst other factors mediated by proteins absorbed from the biological fluid [20] . By designing the macro-and microtopography and chemical properties of the scaffold surface an orientated adsorption of molecules to the surface area can be achieved, creating a specific interface to which the cells and other factors respond to in the following [21] . For example, osteoblast and bone-forming cell function has shown to be increased by targeted adsorption of fibronectin and vitronectin to nanometer-sized grains on the scaffold surface [22, 23] . Functionalising scaffold surfaces can also be achieved through introducing charged groups (such as -OH or -NH 3 ) to the surface, the incorporation of peptide motifs (e.g., RGD), by peptide-polymer hybrid systems (such as protease-sensitive degradation sites) or rDNA protein systems (synthetic artificial proteins resemble specific biological ECM constituents using recombinant DNA) [24] .
Degradation kinetics and mechanical properties of the scaffold also have to be controlled properly and the scaffold should match the characteristics of the tissue present in the defect at the time of implantation as closely as possible [25] . For (musculoskeletal) TE approaches two different strategies can be distinguished from a material science point of view ( Figure 1 ) [26] .
The first strategy requires the physical scaffold structure to support the polymer/cell/tissue construct from the time of cell seeding until the point where the hard tissue transplant is remodelled by the host tissue ( Figure 1A) . In Strategy I, the material must be selected and designed with a degradation and resorption rate such that the strength of the scaffold is retained in vitro and in vivo until the tissue engineering construct is completely remodelled by the host tissue. External or internal fixation systems can be used to shield the tissue engineering construct from the majority of load bearing forces until the hard tissue has matured sufficiently to take the complete load. With this approach scaffolds are not be required to provide complete mechanical equivalence to healthy tissue. However, the mechanical properties of the scaffold should be at least sufficient to support and transmit forces to the host tissue in order to achieve sufficient cell migration/differentiation and tissue remodelling [26] . For Strategy II the intrinsic mechanical properties of the scaffold structure are designed to support cell proliferation and differentiation only up to the point when premature bone or cartilage is placed in a bioreactor. Degradation and resorption kinetics allow the seeded cells to proliferate and secrete their own extracellular matrix (ECM) in the static and dynamic cell cultivation phase while the scaffold gradually resorb/degrades providing sufficient space for new tissue ingrowth ( Figure 1B ). In this strategy, the scaffold serves as a temporary load-bearing device requiring sufficiently high covalent and intermolecular bonding, yet at the same time needs a chemical composition (e.g., aliphatic polyesters) allowing for hydrolytic attack and breakdown.
Degradation and resorption kinetics of the scaffold need to be designed based on the complex interplay of mechanical properties, molecular weight loss and mass loss, and progressive ingrowth of new tissue ultimately replacing the scaffold structure. It is a basic requirement and also one of the fundamental challenges of scaffold design to achieve suitable mechanical properties (in order to retain the designed three-dimensional scaffold structure), yet also to allow breakdown and complete replacement of the scaffold material over time after the new tissue is matured in the scaffold pore space. In bone tissue engineering increased porosity and higher pore size are known to enhance new bone ingrowth on the one hand, but increased porosity may adversely affect the mechanical properties of the scaffold on the other hand [27] . The degradation rate is also directly influenced by porosity and pore size with a higher pore surface area facilitating interactions of the scaffold materials with host tissue thereby accelerating the scaffold breakdown [28] .
Despite their differences regarding scaffold breakdown over time, both strategies share the necessity of a stable mechanical environment provided by the scaffold over a certain period of time in order to achieve optimal tissue regeneration. In 2005 Ioannis Yannas published a theory for induced organ regeneration based on contraction-blocking followed by synchronous isomorphous replacement (CBSIR) [29] that is in accordance with the strategies published in 2000 in a landmark review [26] which discussed in depth the topic of scaffold design and fabrication for bone and cartilage tissue engineering. According the CBSIR theory, tissue engineering scaffolds need to provide temporal mechanical stability at the defect site to prevent scar tissue formation and to guide tissue regeneration. Afterwards, the rate of scaffold template degradation should match the rate of synthesis of new stroma with a spatial configuration that replicates the vanishing template. Both the above outlined strategies and the CBSIR theory provide key evidence and basic considerations on how to design tissue engineering scaffolds in order to achieve best possible regenerative results. They reflect the complexity of the interplay between scaffold and tissue at various stages of re-modelling within the defect site. Exemplarily, Figure 2 illustrates the complex relationship between scaffold properties and newly engineered tissue for bone tissue engineering applications [30] .
When designing scaffolds for tissue engineering approaches, feasibility to translate the technique into clinical application has to be taken into consideration. Design requirements from a clinical point of view include possibilities to produce (and re-produce) scaffolds efficiently at economical costs and with manufacturing process as basic as possible. These aspects will be discussed later in this review. In order to be used clinically, the scaffold must also be able to undergo sterilisation processes. To gain acceptance from the end-user, the physicians, the scaffold should also be easy to handle and not require extensive preparatory procedures before its (at best minimally-invasive) implantation. It becomes clear that despite the fundamental differences between various tissues, there are several considerations to be taken into account regarding the design of tissue engineering scaffold irrespective of the tissue to be regenerated.
In summary, general scaffold design requirements are (i) biocompatibility without eliciting adverse immune reactions and biodegradability with a controlled degradation rate to interact with cell/tissue in-growth and maturation; (ii) a three-dimensional and highly porous structure with an interconnected pore network for cell growth and flow transport of nutrients and metabolic waste; (iii) surface properties which are optimized for the attachment, migration, proliferation and differentiation of cell types of interest (depending on the targeted tissue), (iv) mechanical properties matching those of the tissue implanted into, (v) easy and efficient reproducibility of the scaffold structure in different shapes and sizes, (vi) easy handling without extensive preparatory procedures as well as amenability to sterilisation, (vii) allow the application of surgical implantation procedures as less traumatic to surrounding host tissues as possible (at best minimally invasive implantation) [26, 31] .
Scaffold design considerations are complex with multiple aspects (three-dimensional structure, mechanical and surface properties, degradation kinetics/products, composition of biological components etc.) and their changes over time in vitro and/or in vivo that need to be taken into account [32] [33] [34] . The scaffold therefore has to Figure 2 Schematic illustrating the interdependence of molecular weight loss and mass loss of a slow-degrading composite scaffold plotted against time, which corresponds with tissue regeneration. Scaffold, as shown by SEM (A) is implanted at t = 0 (B) with lower figures (C-E) showing a conceptual illustration of the biological processes of bone formation over time. The scaffold is immediately filled with a hematoma on implantation (C) followed by vascularisation (D) and gradually new bone is formed within the scaffold (E). As the scaffold degrades over time there is increased bone remodelling within the implant site until eventually the scaffold pores are entirely filled with functional bone and vascularity. SEM of scaffold degraded over time (G) with associated schematic visualisation of how mPCL-TCP scaffolds degrade via long-term bioerosion process, which takes up to 36 months in vivo (H). Reproduced with permission from [30] , © Elsevier Ltd. 2012. For further details also refer to Figure 1B and related text.
be considered not as an inert three-dimensional structure, but rather as a conduit for dynamic (chemical, biological and mechanical) extracellular signalling, facilitating a developmentally conducive niche at the site of damage through progenitor cell recruitment, growth and differentiation [15, 31] .
We have provided a set of simple general scaffold design requirements above because evidence indicates that it is of pivotal importance to simplify scaffold-based tissue engineering approaches as much as possible in order to achieve clinical translation. Numerous strategies utilising more and more sophisticated techniques for tissue engineering have been designed, but there is an evident discrepancy between the increasing complexities of proposed tissue engineering therapies compared to the rather basic, simplified nature of actual therapies that have reached clinical applications so far [9] . When looking for example at bone tissue engineering, cell-free approaches have been successfully translated, but cellbased therapies have failed to gain clinical relevance until today [8, 35] . This is of course in part due to the very complex nature of cell-based strategies creating more significant barriers with regards to funding, regulation and approval [9] .
However, we also have to ask ourselves if sophisticated TE techniques aiming to create tissue replacements that resemble the final tissue form in its natural complexity as closely as possible are "over-engineered" from a biological point of view. Do we really need to re-create the structure of the entire organ we ultimately aim to regenerate right from the beginning? Available evidence so far suggests that this is not the case.
Developmental biology clearly shows that normal tissue healing in adults is a complex succession of progressive remodelling of pre-existing tissue structures that exhibit distinctively different mechanical and biological features [36] . For example, during bone fracture healing an initial inflammatory phase is followed by the formation of fibrocartilagenous soft callus that provides mechanical support to the fracture and acts as a template for the bony hard callus (irregular, woven bone) that is replacing the soft callus over time. The final step of bone healing involves the remodelling of woven bone hard callus into lamellar bone consecutively restoring the original cortical/ trabecular bone configuration [37] . During these stages various specific cells cells/tissues are present leading to distinctively different mechanical, chemical and biological features of the healing tissue at different stages. In nature tissue regeneration as the final step in the healing process is achieved only through progressive tissue remodelling, restructuring, and cell re-differentiation; all these processes are developmental in nature and injured tissues are not simply replaced "en masse" by intact ones [36] .
However, many tissue engineers have utilised scaffolds with mechanical and biochemical functions designed to closely mimic the properties of the final tissue that is supposed to be regenerated. Lessons learned from developmental biology suggest that we should rather concentrate on fabricating scaffolds that mimic/promote these metastable, remodelling tissues and enhance cell-cell and cell-matrix interactions instead of precisely engineering the final tissue [36] . It is apparent that a tissue engineering scaffolds cannot orchestrate the natural tissue remodelling process in its entire complexity, and this is not necessary as well. To successfully engineer new tissue, scaffolds rather have to be designed in that they will create a favourable microenvironment to promote/control the (few) crucial steps involved in the remodelling process rather than controlling the entire healing process ( Figure 3 ).
Although we know many of the complex biological processes involved in tissue regeneration in detail now and are able to reproduce the players (growth factors, stem cells, ECM etc.) involved to a certain extent, we also have to pay attention to the role of the host tissues endogenous healing capacity in the process of tissue engineering. Instead of completely replacing the damaged tissue with sophisticatedly engineered tissue constructs, promoting and directing the host tissues endogenous capacity to replace/regenerate the damaged tissue will most likely be more successful from a developmental biology point of view in tissues with a high endogenous regeneration capacity, such as bone. However, it has to be mentioned that some tissues (non-vascularised tissues such as articular cartilage or highly vascularised tissues such as kidney or heart) possess very limited endogenous healing capacity and will therefore require even more sophisticated tissue engineering to stimulate and guide healing.
Yannas and co-workers have recently provided evidence for such beneficial modifications of the healing process guided by acellular scaffolds [10, 38] . The researchers were able to show that severe wounds in skin and nerve tissue become spontaneously populated with contractile cells in the absence of a scaffold. These contractile cells then deform the defect site of the organ in order to achieve rapid wound closure leaving no sufficient space for regenerating tissue to form. Additionally, contractile cells hamper tissue regeneration via synthesis of a dense collagenous scar tissue that sterically prevents direct and physiologic growth of dermis or neural tissue. In the presence of a sufficient scaffold material, the density of contractile cells is significantly reduced in both tissues with suppressed wound contraction leading to reduced scar formation and enhanced regeneration. The authors have identified these as essential (scaffold-based) modifications of the healing process that must be realised before regenerative activity in skin and neuronal tissue (and supposably in other organs such as liver or conjunctiva as well).
The reduction of contractile forces and maintaining a three-dimensional template structure is also a key role in the early interaction between bone tissue engineering scaffolds and host tissue fluids: After implantation of a scaffold material into the bone, a fibrin clot is established at the scaffold surface from the host's body fluids, mainly hematoma. Through this temporary fibrin matrix osteogenic cells migrate to the surface of the scaffold. In the absence of a scaffold, the migration of osteogenic cells through the fibrin matrix leads to retraction and deformation of the clot [39] . However, the presence of a rough scaffold surface can tightly secure the fibrin matrix in place, thereby guiding migration of osteogenic cells into the defect site [40, 41] . This modification/guidance of the healing process has been defined as "osteoconduction" [42] and is one of the key requirements of a bone tissue engineering scaffold according to the diamond concept [43] . In analogy to preventing scar tissue formation in skin and nerve tissue, scaffolds can thereby also prevent non-union in bones (that is formation of non-mineralised non-bony scar tissue) by reducing contractile forces at the defect site. The reduction of contractile forces in the defect site to prevent scar formation is an explicit example of how scaffolds can enhance tissue regeneration by controlling only a few, yet crucial steps in the healing process.
The value of allogenic and autologous cells for tissue engineering has been reviewed by Mason and Dunhill in 2009 [44] . Although we are now able to isolate and proliferate a number of (stem) cells, available evidence suggest that exogenous addition of cells and growth factors/ cytokines to regenerate tissues is only required in the minority of cases and can even have adverse effects on the outcome: The woundbed and wound edges in fullthickness skin wounds as well as the stumps in transected peripheral nerves are well-known suppliers of keratinocytes, fibroblasts and endothelial cells or Schwann cells, fibroblasts and endothelial cells, respectively [10] . Soluble regulators and other signalling molecules are also naturally present in the wound exudate and data suggests that in most cases endogenous supply of reactants/cells suffices to provide necessary signalling events and cell differentiation that will eventually lead to tissue regeneration [10] . As Yannas has pointed out, several studies on skin wound healing with exogenous addition of cytokines and growth factors have failed to regenerate stroma (dermis) in vitro and in vivo [45, 46] , while regeneration of both dermis [47] and peripheral nerves [38] was achieved with scaffolds free of soluble exogenous factors/cells. Other findings which revealed that the success of many transplanted cell-scaffold constructs actually resulted from death of most implanted cells, remodelling of the synthetic ECM scaffolds and repopulation with endogenous, patient-derived cells support this concept [36] . The authors concluded that engineering a regenerative microenvironment that promotes/supports endogenous supply is most often sufficient and only larger sized defects may require exogenous addition of cells and reactants.
This concept also translates to bone tissue, where stem cell and vascular niches are often severely compromised in critical sized bone fractures or in the context of revision surgeries [48, 49] . Biomimetic scaffolds for bone tissue engineering are designed to re-constitute a developmentally conducive niche at the site of damage in vivo to re-establish the vascular network and recruit skeletal stem cells [31] . In creating this regenerative microenvironment, cell-free scaffold approaches have proven to be highly efficient in bone tissue engineering and have also been successfully translated from bench to bedside for example in the use of polycaprolactone burr whole plugs and scaffolds for orbital floor reconstruction or other cranioplasties [19, 50] .
However, for large defects (in skin, nerves or bone tissue) the use of cell-seeded scaffolds may become necessary as cell regeneration is thought to be limited by distance of migration [51] . But large scaffold constructs often develop hypoxic conditions and a build up of harmful metabolic waste products in the central scaffold areas until a sufficient vascular network has been re-established. Such harsh condition will pose a significant risk to exogenously added cells and will lead to high percentages of cell necrosis. If exogenous cells are applied, it is therefore imperative to apply these cells at a point in time when an adequate microenvironment is present in the defect site in order to optimise cell survival. The first stage of bone fracture healing consists of a robust acute inflammatory response to the injury during which macrophages and other inflammatory cells are present in the defect site [52] . Such brief but highly controlled secretion of proinflammatory molecules following an acute injury is known to be critical for tissue regeneration [53] . While during the inflammation reaction macrophages and platelets are present in the defect area, the predominant cell type changes to endothelial cells, mesenchymal stem cells (MSCs) and chondrocytes during the following soft callus phase [54] . The fact that MSCs are not found during the first (inflammatory) phase of bone healing indicates that the microenvironment for these highly potent cells has to be formed first before MSCs are homed to the defect site. Nevertheless, many cell-laden bone tissue engineering constructs are implanted directly into the defect site at the time of defect creation. This will expose the MSCs to the harsh inflammatory (and possibly hypoxic) conditions and often leads to low survival rates of the implanted cells. Taking the biological microenvironment in the defect site and its changes over time into account, we have recently designed a method of delayed injection of MSCs into a critical sized tibial defect in our ovine large animal model (Figure 4 , data not published yet) [55] . Four weeks after the initial creation of the critical sized bone defect (hence at a time when the acute inflammatory phase has subsided and MSCs would naturally be present in the healing defect) allogenic MSCs were injected percutaneously into the defect site. We hypothesised that the delayed injection into a microenvironment more suitable would increase cell survival and thereby bone regeneration. Our results so far do indeed demonstrate increased rates of bone formation for the delayed injection model with the study still under investigation.
In summary, a minimalistic approach to scaffold design promoting only a few but crucial steps in the endogenous healing process, as well as respecting the biological microenvironment and its changes over time when using exogenous cells/biological factors are promising strategies to optimise current tissue engineering approaches. Develop mental biology and the hosts own tissue healing effort can teach us valuable lessons to avoid "overengineered" approaches to tissue regeneration thereby at the same time making clinical translation easier and more likely to happen. This is an important consideration, because although scaffold-based tissue engineering techniques have been investigated for more than three decades now and many different approaches have been developed, the majority of these techniques are still under scientific evaluation and only a very limited number has been translated from bench to bedside yet. For example, more than 12000 scientific publications are available on "bone tissue engineering" and more than 2000 publications focus on "bone tissue engineering scaffolds" [56] . In stark contrast to this plethora of scientific publications, the number of clinically available (bone) tissue engineering products can be counted on one hand [57, 58] . One of the most important (and also probably one of the most underestimated) reason for this discrepancy is the lack of defined clinical target applications and suitable business models for many tissue engineering approaches. Hollister et al. [34, 56] have reviewed barriers between scaffold based bone tissue engineering concepts and their clinical translation, identifying three main areas of challenges: Technical scaffold demands, business challenges and philosophical challenges (strategic challenges relating to funding and publication priorities). According to the authors, technical demands can be summarised as the "4 Fs": Form (scaffolds need to fill complex three-dimensional bone defects), Function (scaffolds need to provide temporary mechanical stability at defect site), Fixation (secure attachment to host tissue), and Formation (scaffolds are required to enhance new tissue formation by providing adequate microenvironment) [9] . Business barriers include (but are not limited to) gaining regulatory approval (the most cost intensive challenge), obtaining external funding for product development as well as obtaining physician acceptance and approval for insurance reimbursement.
Philosophically (/strategically), scaffold translation from bench to bedside faces challenges with regards to choosing between fundamental scientific research models ("linear" vs. "quadrant" models) [59] , the paucities of clinically relevant preclinical large animal models and different focuses of scientific research and commercial companies (publication vs. commercialisation). Although defined for bone tissue engineering approaches by the authors, these fundamental challenges apply to the tissue engineering field in its entity. In order to successfully translate scaffold-based tissue engineering approaches from bench to bedside, it is imperative to carefully address each of these challenges independently and optimise the design of the approach in this respect.
Scaffold material
Given the fact that all tissue engineering scaffolds must ultimately be applicable in the human body, one of the key scaffold requirements is that the materials used are non-carcinogenic, non-toxic, non-teratogenic and possess a high cell and tissue biocompatibility (commonly defined as ability of a material to perform with an adequate response in a specific application [60] ). In general, three different generations of biomaterials used for (orthopaedic) tissue engineering scaffolds and (orthopaedic) implants can be distinguished: the first generation consists of biologically inert materials that function mainly as space holders, such as bio-inert metals or polymers without specific coating due to their lack of bioactivity or degradability, first generation materials are nowadays mostly used in combination with second and third generation biomaterials. Second generation biomaterials are either bioactive or bioresorbablematerials that exert active functions on the tissue they are implanted in by surface interactions ( = bioactive) or clinically relevant controlled chemical breakdown and resorption ( = bioresorbable). Second generation biomaterials include metal alloys (titanium, cobalt chrome, stainless steel, aluminium etc.), bioactive glasses (and hybrid materials), bioactive ceramics (such as hydroxylapatite and other calcium phosphates, aluminum oxide, carbon), glass-ceramics as well as biological or synthetic polymers (e.g., polycaprolactone, poly lactides, poliglycolides, polymethylmethacrylate), and composites of these materials.
Biomaterials of the third generation are designed to stimulate specific cellular responses on a molecular level [61] . These "smart materials" can influence cellular functions by releasing bioactive molecules and/or exhibiting bio-mimetic surfaces closely resembling the natural healing environment of tissues. Several comprehensive reviews have been published on this topic [62, [63] [64] [65] [66] [67] and it is beyond the scope of this review to cover the literature entirely. To give a few examples, bio-mimetic nanohydroxyapatite composite scaffolds with nanofibrous and nanoporous topographies mimicking native bone matrix have been shown to control osteogenic differentiation of hMSCs and induce new bone matrix formation in vitro and in vivo [68] . Surface modifications can also be used to selectively promote adhesion of specific cells, the petide Lysine-Arginine-Serine-Arginine (KRSR) for example selectively promotes adhesion of osteoblasts to scaffold surfaces [69] . Bioactive molecules released from smart biomaterials include (but are not limited to) targeted delivery of growth factors in bone tissue engineering, such as bone morphogenic protein (BMP), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), insulin-like growth-factor 1, vascular endothelial growth factor (VEGF) [39, 70] . The extracellular matrix (ECM) and its own dynamic composition acts as a reservoir for soluble signaling molecules and mediates signals from other sources to migrating, proliferating, and differentiating cells [71] . A key aspect is therefore to design scaffolds in order to mimic the natural ECM and its dynamic release of bioactive molecules in tissue healing processes.
A variety of natural and synthetic polymers [72] [73] [74] , ceramics [75] [76] [77] [78] and composite materials [79] [80] [81] has been developed and investigated for the use in tissue engineering scaffolds over the last years. This review focuses on the design and fabrication of TE scaffolds and a comprehensive presentation of the plethora of materials investigated for tissue engineering in the past decades is clearly beyond the scope of the review. Given the numerous materials and modifications to select from for manufacturing scaffolds, again, the focus has to be on clinical translatability and "over-engineering" (as discussed above) has to be avoided. To evaluate how "smart" biomaterials really need to be, is a (if not the) key aspect of any translational science approach in tissue engineering and we have addressed this matter comprehensively in another review recently. It is the authors opinion that biodegradable synthetic polymers (and composite materials hereof, e.g., in combination with tricalcium phosphate) are, from a material point of view, of key interest for the devolvement of new scaffold-based tissue engineering strategies [26, 74] . As most tissues perform multiple functional roles and exhibit a largely inhomogeneous distribution of cells and structural properties, it is unlikely that a single scaffold material could serve as a universal foundation for the regeneration of even a single tissue, not to mention an entire organ. Natural materials such as bone are composite materials that possess unique mechanical and biological characteristics mostly unmatched by human made materials. The microstructure of bone consists of hierarchically organised highly dispersed bone mineral nanocrystals and collagen fibrils, bone behaves as a tough material at low strain rates (0.001/s) but as a brittle material at high strain rates (1000/s) [64] . Synthetic (or natural) composite materials that enable the combination of distinctively different mechanical properties with various biological characteristics therefore have to be considered of key interest for TE/RM strategies.
A critical issue in scaffold-based tissue engineering is the organisation of cells and ECM into a three-dimensional architecture that closely resembles the native tissue that is being replaced and/or repaired in both its complex structure and distinct functionality. In the last decade, significant technical innovations (using synthetic polymers) have profoundly impacted this issue as will be reviewed in the next chapter.
Scaffold fabrication
As outlined above, it is imperative to control the structural properties of tissue engineering scaffolds not only on a macroscopic scale, but also on a microscopic and nanometre range in order to design successful tissue engineering constructs. A variety of conventional fabrication techniques have been utilised in the past to manufacture different materials into scaffolds for tissue engineering purposes. These techniques include (but are not limited to) solvent casting and particulate leaching, gas foaming, fibre meshes and fibre bonding, phase separation, melt moulding, emulsion freeze drying, solution casting and freeze drying [82] . Although each of these techniques has its very own advantages and disadvantages to be considered, there are some common shortcomings for all of these methods: Conventional scaffold fabrication methods do not allow the precise control of pore size, pore geometry, pore interconnectivity or spatial distribution of pores and interconnecting channels of the scaffolds fabricated ( Figure 5 ) [19, 83, 84] . In addition, some of the techniques involve organic solvents and/or other toxic substances raising concerns of potential toxic or carcinogenic effects of substance residues in the scaffolds after fabrication [83] .
Developed in the 1980s and initially mainly applied in telecommunication and car industries, additive manufacturing (AM) techniques have significantly contributed to overcoming many of these limitations [5, 19, 27, 34, 82] . The terms Solid FreeForm Fabrication (SFF) and Rapid Prototyping (RP) have also been used to refer to these techniques in the past. However, the latest ASTM standard now summarises the multitude of these techniques under the term "Additive Manufacturing" [85] . The term was chosen to emphasise that in contrast to conventional scaffold fabrication methods (that are subtractive in nature, removing parts of the scaffold structure to create desired porosities and pore size) AM techniques are using an additive layer-upon-layer manufacturing approach. In AM a digital model of the three-dimensional structure to be created is designed using Computer-Aided-Design (CAD). The data can either be acquired by complete de novo CAD or taken from preexisting three-dimensional scans (such as MicroCT, clinical CT, MRI, Ultrasound, digital Photogrammy). The CAD structure is then expressed in a Standard Tessellation Language (STL) format for the AM machine. Before the manufacturing process, the STL model is expressed as an accumulation of two-dimensional sections through the structure to be created. The data are then transferred to the AM machine that created the three-dimensional structure in a layerupon-layer production process. A number of AM techniques exist using either thermal, chemical, mechanical or optical spatially directed reactions or a combination of these to fabricate the scaffold structure [5] . In this review we present only the four AM techniques that are most commonly used in the fabrication of tissue engineering scaffolds ( Figure 6 ). We also provide some examples of how these techniques have been used in tissue engineering (and clinical applications) so far. For further details the reader is referred to recently published comprehensive reviews [5, 34, 74, 86] . Potential future applications of AM techniques are also highlighted later in this paper in the section on "Additive Tissue Manufacturing".
Melt extrusion/fused deposition modeling (FDM)
In Melt Extrusion/FDM, three-dimensional structures are fabricated by computer-controlled nozzle-based application of ultrathin liquid layers of melted thermoplastic filaments or granules. The material hardens and adheres with the next layer to form a solid structure. Advantages of the application of Melt Extrusion/FDM techniques are the utilisation of relatively simple technologies and therefore low costs enabling fast and cost-effective manufacturing processes. On the downside, FDM requires strong filaments and high temperatures making the co-processing of viable cells difficult. Also, the range of materials that can be used is limited.
Scaffolds manufactured by FDM technique have been used to culture fibroblasts and osteoblast-like cells in an entirely interconnected 3D medical-grade polycaprolactone (mPCL) matrix [87, 88] . FDM-fabricated PCL scaffolds were also applied in an ovine large animal model to regenerate critical sized tibial defects [89] . The scaffolds have furthermore been translated successfully into clinical practice and a large number of patients have been treated with mPCL-burr whole plugs and mPCL-scaffolds manufactured by FDM for orbital floor reconstruction and other cranioplasties so far [19, 50] .
Stereolithography (SL)
SL uses an ultraviolet laser to cure and solidify a photosensitive polymer when it makes contact with the resin. The laser is applied to the liquid polymer solidifying specific locations of each layer on platform. After one layer is finished, the platform is lowered and the overlying sheet is created the same way. When the entire structure is manufactured, excess polymer is drained and can be reused. The laser can either be administered irradiating a partly opaque patterned mask to transfer the structural shape onto the polymer or a focused UV beam can be used to produce the structures directly and with higher accuracy (direct writing). SL is the AM technique with the highest local resolution and accuracy, using two-photon STL-techniques to initiate the polymerisation scaffolding structures even at micrometer and sub-micrometer level can be created [90] . However, there is only a limited choice of photo-polymerisable and biocompatible materials available for SL applications. It is possible to use different materials by draining all the resin material from the chamber and refilled it with the different material if the desired layer is reached. Potential errors include overcuring, which occurs to overhang parts lacking fusing with a bottom layer. Because of the use of high-viscosity liquid the layer thickness is also (to a certain amount) variable introducing an error in the border position control. All these errors are minimized in equipment's of high quality.
SL can for example be used to fabricate three-dimensional vascular microcapillary structures on a micrometer level by two-photon polymerisation techniques [90] . Other investigators have used SL to create hydroxyapatite scaffolds with distinct pore network architectures for bone tissue engineering applications in small animal models [91] . For further reading on the use of SL in biomedical applications and tissue engineering we recommend detailed reviews published by Melchels et al. [5, 92] .
Inkjet printing/3D printing
In this printer-based technique a liquid adhesive material is applied to the surface of a powder via a printerhead solidifying the powder where the three-dimensional structure is to be formed. While initially conventional inject-printers had been modified to suit the requirements of this technique, more sophisticated machines have been developed to enable the use of different materials and also to co-print living cells in a sterile environment. Particular advantages of inject printing are the low costs (use of existing inexpensive technologies), fast processing and the potential use of multiple compositions. Limitations include weak bonding between powder materials and therefore relatively low mechanical strength as well as a rough surface [5, 82] . Seitz et al. produced custom-made three-dimensional ceramic scaffolds for bone tissue engineering by using a powder-based 3D printing technique, consolidating the scaffolds at high temperatures in a second step [93] . Giordano et al. created dense structures from polylactic acid (as a bioresorbable polymer that can be used for tissue engineering applications) via 3D printing, further improving the mechanical properties of the printed structures by cold isostatic pressing [94] . In an indirect 3D printing approach, Lee et al. successfully created custom scaffolds mimicking human mandibular condyle using polycaprolactone and chitosan for potential osteochondral tissue engineering [95] . Bone marrow stromal cells (BMSC) cultured on these scaffolds showed good viability and apatite coating further enhanced cellular spreading and proliferation. Luangphakdy et al. evaluated different osteoconductive scaffolds fabricated by 3D printing, laser stereolithography, or solvent casting from various materials [including poly(L-lactide-co-glycolide) (PLGA), poly(L-lactide-co-ε-caprolactone) (PLCL), tyrosine-derived polycarbonate (TyrPC), and poly(propylene fumarate) (PPF)] in a canine femoral multi-defect model for bone tissue engineering [96] . Various 3D printing applications are also frequently used in tissue engineering approaches based on matrices ( = hydrogels) as we will outline briefly later in this review (see chapter "Additive Tissue Manufacturing").
Selective laser sintering (SLS)
This AM technique uses a carbon dioxide laser beam to sinter and fuse a powder material in the building chamber. The chamber is heated just below the melting point of the powder material used; afterwards the laser beam selectively heats and solidifies the powder above melting point in selective areas tracing the shape of the object to be built. After each layer is hardened, the piston is repositioned and new layer of powder is added above the solidified thin layer. Advantages of SLS include its high accuracy (limited by the size of particles of the biomaterial), good mechanical strength, the option to use a wide range of powder materials and the possible recycling of unused powder material. Shortcomings of this technique are the need for high local temperatures during the SLS process (unsuitable for concomitant application of cells), oxidation processes need to be avoided by using an inert gas atmosphere and potentially entrapped powder residues can be difficult to remove [5, 82] . Antonov et al. published a modified method of "surface-selective laser sintering" (SSLS) to fabricate three-dimensional biodegradable and bioactive composite scaffolds (spatial resolution ~200 μm) from poly(d,l-lactic) acid and carbon microparticles [97] . The melting process is reported to be limited to only the surfaces of each particle, opening up a potential route to include delicate, non-heat resistant bioactive species within each particle that can retain their activity throughout the manufacturing process, as demonstrated by the incorporation of the enzyme ribonuclease A into particles (the enzyme retained substantial activity).
Williams et al. used polycaprolactone scaffolds fabricated via selective laser sintering (SLS) in an ectopic mouse model to investigate new bone formation [98] . To demonstrate potential clinical applications of their scaffolds, the authors also fabricated a prototype mandibular condyle scaffold based on an actual pig condyle by SLS.
Other applications of SLS in tissue engineering, and at-large in the biomedical field, are also reviewed and discussed in a recently published paper [99] .
AM provides the tissue engineer with a powerful tool to exert distinct control over the scaffold architecture on a micrometer scale. As highly sophisticated three-dimensional structures can be designed virtually by CAD, the AM process is mainly limited to computational capacity and local resolution of the AM technique applied. In general, optical-based AM techniques achieve the highest resolution with STL being the most accurate: Using STL or twophoton STL techniques objects at a scale of around 20 µm or even at micrometer and sub-micrometer levels can be fabricated, respectively [90, 92] . Figure 7 shows different 3D scaffold systems of various porosity and pore geometry fabricated via FDM as an example of how distinctly AM enables the control of scaffold architecture [26] . The meticulous fabrication of scaffold ultra structures via AM allows the design of applications with areas of spatially inhomogeneous structural integrity, e.g., scaffold areas of increased blood flow due to increased porosity. Scaffolds with different spatial distributions of porosities, pore sizes, mechanical and chemical properties could be applied to further optimise tissue engineering techniques by better mimicking the naturally inhomogenous composition and architecture of body tissues. For example, bone tissue engineering scaffolds with gradients in porosity and pore sizes can used to enhance vascularisation and direct osteogenesis in one area of the scaffold (larger pores), while promoting osteochondral ossification in the other (smaller pores) to reproduce multiple different types of tissues and tissue interfaces within one and the same biomaterial scaffold [28] .
Since the introduction of AM into the field of tissue engineering, these techniques have been applied in various ways and for numerous tissues as has been recently reviewed [5, 26, 86, 100] .
Future outlook: image-guided tissue engineering, additive tissue manufacturing and in vivo tissue engineering
Although AM techniques have significantly improved the way scaffolds are designed and fabricated, we are still far away from the ability to regenerate or replace entire organs with custom made tissue engineering constructs, as was envisioned to become reality soon more than 30 decades ago [101] . However, the interdisciplinary nature of tissue engineering approaches has led to promising innovations that may become clinically available in the near future.
Combining modern digital imaging techniques (CT, µCT, MRI, Ultrasound, 3D digital photogrammy) with CAD and AM techniques we are already able to create highly detailed, three-dimensional models for any individual bone defects to plan surgical approaches, locate osteotomy sites, choose the correct orthopaedic implant and to predict functional as well as cosmetic outcomes [102, 103] . Applying these technologies also allows the design and fabrication of custom-made patient-specific surgical implants and tools [104] . Taking this approach one step further, these techniques can also offer the option of an automated fabrication of patient-specific scaffolds in "image-guided tissue engineering" approaches [105] . So far, a number of tissues have been addresses using image-guided tissue engineering approaches, including menisci [106, 107] , cartilage [108] and bone tissue [109, 110] (Figure 8 ). The ability to tailoring the outer (and inner) scaffold structure exactly to the patient-and organspecific needs by AM will no doubt be beneficial to any future tissue engineering application. With the identification of new biomaterials suitable for these techniques and further innovations in digital imaging, the fabrication of customised scaffolds using automated AM techniques holds a significant opportunity to produce scaffolds with reproducible and mathematically predictable structural properties in a clinically highly relevant context at economical scale.
In their definition from 1988, Skalak and Fox stated that "the basic point […] is that tissue engineering involves the use of living cells.
[…] The definition is intended to encompass procedures in which the replacements may consist of cells in suspension, cells implanted on a scaffold […] and in cases in which the replacement consists entirely of cells and their extracellular products [1] ." Interestingly, 25 years after their definition that cells are one basic point of TE and while today approaches implanting (primarily) cell-free scaffolds (that are populated by the hosts' cells later) have been successfully applied in clinical applications (e.g., for bone, cartilage and skin) [50, [111] [112] [113] , while cell-seeded scaffold strategies have so far failed both clinically and economically [8, 35] . Natural tissues display a distinct highly organised macro-and micro-architecture with complex spatial distributions of various cell types and extracellular components. It is therefore unlikely that a single scaffold material will be able to regeneration of even a single type of tissue, not to speak an entire organ, which often exerts multiple functions and is composed of multiple highly specialised tissues portions. During the last years various methods have been applied to create "tissue engineering constructs" (TEC) combining different bioactive materials with living cells and/or active biological molecules (such as growth factors). For example, in bone tissue engineering, TEC combining osteoinductive three-dimensional structures with osteogenic cells and osteoinductive factors have been manufactured to repair critical sized bone defects [30, 89] . However, manual post-processing of scaffolds (seeding cells on to scaffolds and culturing pre-fabricated scaffolds, incorporating growth factors etc.) to create TECs is time consuming and the spatial distribution of cells and bioactive factors in the TEC is not well controllable. Particular shortcoming of the current approach include the inabilities to mimic the cellular organisation of natural tissues, to address vascularisation of the TECs and to upscale to (economically feasible) clinical applications [5] . Addressing these shortcomings the novel approach of "Additive Tissue Manufacturing" (ATM) (also termed "Bioprinting") aims at simultaneously processing living cells and biomaterial constructs in a computer controlled TEC-fabrication process [5, 86, 114] . Fabricating tissue engineering applications that mimic entire organs (with complex spatial distribution of various cell and biomaterials) in a single computer-controlled process facilitates distinct control over the tissue assembly and also holds promising opportunities for economical and clinical upscaling. ATM has so far been investigated mainly in "bottom up" [115] ( = scaffold free) tissue engineering approaches using matrices ( = hydrogels) rather than cellular solids.
Units of aggregated vascular cell types (including smooth muscle cells and fibroblasts) were printed layerby-layer concomitantly with agarose rods in scaffold-free vascular tissue engineering using bioprinting applications [116, 117] . Human fibroblasts and bovine aortic endothelial cells have been used in three-dimensional, directwrite cell deposition systems with different materials to manufacture spatially organised viable structures and have been successfully cultured in these constructs for up to 35 days after fabrication [118] . Three-dimensional structures composed of hepatocytes and gelatin/alginate hydrogel have been printed and the embedded hepatocytes were reported to remain viable performing biological functions in the construct for more than 12 days [119] . Multilayer photopatterned PEG hydrogel structures have also been printed to culture hepatocytes in a threedimensional environment [120] . For further details and comprehensive overviews on bioprinting and hydrogels, the reader is referred to a review recently published by our research group [5] as well as to a review published by Malda et al. [4] .
Albeit the feasibility of bottom-up tissue engineering approaches, the presence of a scaffolds structure is often beneficial because it provide mechanical strength while the Extracellular Matrix (ECM) is regenerated and the assembly of large cellular constructs purely from sheets and clusters is limited by transport of oxygen and metabolic products until a vascular system develops [86] . Hybrid approaches combining seeded cells and structurally organised ECM-mimicking biomaterials are most likely to resemble the conditions in natural tissues. Currently, many AM techniques used in TE scaffold fabrication require process parameters (e.g., high temperature, solvents, lack of water) that do not allow the direct inclusion of living cells and often AM techniques to specifically designed for the use of a single type of material only [5] . These limitations need to (and will potentially be) overcome in the future enabling the fabrication of hybrid structures composed of solid biodegradable materials with cell-laden hydrogels for TE. A first approach has recently been realised by generating a viable construct of alternating thermoplastic fibres and cell-laden hydrogels [121] . This approach yields novel organised viable hybrid constructs with controllable mechanical characteristics (that can be designed to the same range as those of the tissue to be regenerated), spatial control over cell and biomaterial deposition and also allows the use of multiple hydrogels, thus can produce constructs containing multiple cell types or bioactive factors. Such hybrid applications are most promising strategies and we have recently provided a rationale for the potential use of ATM hybrid constructs in breast tissue regeneration after mastectomy ( Figure 9 ) [5] . Albeit today clearly at their scientific infancy, ATM and Bioprinting offer the tissue engineering field a promising approach to design complex organ-like constructs accounting for the complex structure of natural organs. In the future, automated tissue assembly may become available for scalable and reproducible mass production of tissue precursors, also allowing the implementation of Good Manufacturing Practices (GMP), quality control and legislation [122] .
Nevertheless, seeking to optimise tissue engineering approaches from an engineer's and/or material scientists' point of view by developing more and more sophisticated machines, techniques and biomaterials (and combinations thereof) will not be the only road to success. Tissue engineering endavours following an in vivo tissue engineering approach have also yielded successful and promising results so far. For a better understanding, it is necessary to distinguish between TE ( = the implantation of in vitro seeded matrices or scaffolds) and "Guided Tissue Regeneration" (i.e., implanting initially acellular matrices/scaffolds into a host tissue that are re-populated by the hosts autologous cells after implantation) [123] . This approach takes advantage of the host tissues own healing capacity and uses the body as a bioreactor instead of culturing implants in an extracorporeal bioreactor first. As we have discussed above, guided tissue regeneration requires the scaffold for the control of only a limited set of specific, yet crucial steps in the healing process to promote tissue formation and maturation. For example, using a periosteal-based in vivo bioreactor approach large volumes of new bone have been generated without the need for exogenous cells or growth factors by injecting calcium alginate hydrogel between the cambium layer of the periosteum creating an adequate extracellular matrix microenvironment [14] . Another in vivo bioreactor for bone tissue engineering has been shown to recruit endogenous pluripotent cells from circulating blood to a vascularized coralline scaffold supplemented with bone morphogenetic protein-2 (BMP-2) and induce new bone formation [124] . Further guided tissue regeneration studies have proven that appropriate biological stimuli can elicit a recruitment of local cellular populations instructing these cells to contribute to endogenous tissue regeneration [125, 126] . Studies on decellularised constructs of complex organs such as the heart, liver, and lungs that were re-seeded with cells (in vitro and in vivo) have also yielded promising results so far, further emphasising the importance of the ECM scaffold as mediator for tissue regeneration that can be repopulated with (endogenous) cells successfully [127] [128] [129] .
However, there are certain situations where the addition of external cells and growth factors may become necessary, especially if the local microenvironment is heavily disrupted (e.g., by severe infection or degenerative disorders) and cannot be recreated in situ by a cell-free scaffold and/or if the hosts reservoir of endogenous cells and biological factors is diminished (through chemotherapy/ radiation therapy, for example). If orthotopic sites are compromised in such way, ectopic implantation and in vivo cultivation with secondary implantation of the ectopically regenerated tissue into the defect can also be considered. The field of "In vivo Tissue Engineering" takes up the basic idea of Guided Tissue Regeneration to utilise the body as intrinsic bioreactor but combines bioactive scaffold with exogenously addition of cells/biological factors to achieve best possible results (Figure 10) . The clinical potential of in vivo TE has been strikingly demonstrated in a human patient by growing a tissue-engineered mandible (made from a titanium mesh cage filled with bone mineral blocks and infiltrated rh-BMP 7 and 20 mL of the patient's bone marrow) ectopically in the latissimus dorsi muscle and successfully transplanting the construct as a free bonemuscle flap to repair a mandibular defect 7 weeks later [130, 131] . Tissue-engineered ears have also already been grown in human patients by ectopically culturing autologous auricular chondrocytes in the lower abdominal wall before being surgically explanted, sculptured into an ear framework and implanted orthotopically [130, 131] . These examples demonstrate that in vivo TE is capable of generating patient-specific implants with regards to the cellular and immunological status, offering a preferential route for TE therapies to be utilised within clinical settings. The current state of the art and future directions of in vivo TE have been reviewed recently by McCullen et al. [11] and Shastri [132] . Figure 10 Strategies for in vivo tissue engineering involve (i) the prefabrication of a scaffold, growth factors, and exogenously seeded cells or combinations thereof; (ii) subsequent implantation into the orthotopic or ectopic site for cultivation; (iii) upon implantation the local microenvironment created by the scaffold via soluble degradation products such peptides or ionic species can promote stem cell homing via chemoattraction and tissue formation; (iv) in situ vascularisation and/or cellular colonization occurs throughout the entire construct; (v) the implanted construct is functional in situ or can be reimplanted to the tissue defect site. Reproduced from [11] , © 2011 Elsevier Ltd. All rights reserved.
Conclusion and future directions
Undoubtedly, scaffolds play a very important part in today's tissue engineering/regenerative medicine strategies and will continue to do so in the future. The design, fabrication and application of TE scaffolds constitutes a challenging intersection between various scientific fields [including engineering, (developmental) biology, chemistry, physics, informatics, medicine etc.] and "few areas of technology will require more interdisciplinary research than tissue engineering", as stated by Langer and Vacanti in their 1993 landmark paper [2] .
The field of TE/RM has undergone a significant evolution during the last 30 years. From a material science point of view, we have seen the identification of existing biomaterials and techniques that can be used to design and fabricate scaffolds and their translation into clinical practice. Additionally, the development of novel bioactive materials along with technical innovations of fabrication methods has led to significant improvements in the field of TE/RM. From an engineering point of view scaffold design and fabrication should follow the golden rules practised in other high-tec industries namely embrace complexity, design modularity and deliver simplicity.
From a biological point of view, the last three decades have seen an extensive gain of knowledge on cell-cell and cell-scaffold/matrix interactions, as well as on developmental biology and physiological processes involved in adult tissue healing. We are at the beginning of an era where we will be able to design scaffold properties that target specific molecular processes in a cellular healing microenvironment that can be best described as ''defined noise'', punctuated by sharp signals [132] . The biological challenge in TE/RM is how to modulate this microenvironment without significantly altering the delicate balance of information, such that key events of developmental biology and adult tissue healing can be repeated (recruitment of pluripotent cells, angiogenesis, differentiation of cells into tissue-specific phenotypes, and achieving polarity within the tissue environment) [132] . Exogenous cells and growth factors may be applied under certain circumstances, but are no longer an essential core component of tissue engineering approaches as defined by Skalak and Fox in 1988 .
From a medical point of view, patient-specific TE/ RM approaches with high translatability from bench to bedside are emerging in the form of Image Guided Tissue Engineering, ATM and in vivo TE. In case of the above mentioned tissue-engineered human mandible [130, 131] that has been applied in a human patient, the researchers have combined Image Guided Tissue Engineering (manufacturing a patient specific titanium mesh-cage with clinical data from a three-dimensional computed tomography scanning and computer-aided design techniques) with an in vivo TE strategy in the patient's own latissimus dorsi muscle. This is an excellent example how combining several novel TE techniques can be highly beneficial to optimise our scaffold-based TE strategies and to generate patient-specific implants not only with regards to externals size and shape but also in terms of biological status (autologous cells, immunological status etc). It furthermore shows that the interdisciplinary research approach proclaimed by Langer and Vacanti is of uttermost importance in order to achieve best possible scientific output and ultimately gain clinical application and acceptance.
Emerging challenges for the field of tissue engineering are (i) to clearly identify how much extrinsic physiochemical information is required to mobilise endogenous/ transplanted cells into producing a complex tissue, and (ii) what minimum level of material complexity is required for a given task [133] , (iii) the identification of tissue/organ defects where cell-free approaches will suffice and those defects that require external addition of cells/biological factors (iv) the development of clinical diagnostic tools to reliably distinct between these two entities (v) the combination of novel innovative TE techniques such as Image Guided TE, ATM and in vivo TE to optimise our strategies while (vi) focussing on clinical translation and application of these TE strategies. TE/RM should not only aim for high-impact research that advances the boundaries of scientific knowledge but should also contribute to the betterment of society (i.e., advance the current health care of our nations) because otherwise the huge (governmental and private) funding efforts will not yield a significant socioeconomic outcome. Current and future tissue engineering approaches should therefore be measured on the success of translating (scaffold-based) techniques from laboratory bench to routine clinical application.
